AI Image
4 red flags – and 1 truth – amid the peptide hype
USA Today • • business
Key Points:
- Experimental peptides, popular among longevity and antiaging advocates, lack FDA approval for safety and effectiveness, yet efforts led by Health Secretary Robert F. Kennedy Jr. seek to increase their accessibility despite scientific warnings.
- Peptide promoters often make misleading claims, such as peptides not being drugs, being safe because they are natural, and effectively treating various illnesses, though these assertions lack robust clinical trial evidence.
- Many peptides, including BPC-157, have not undergone rigorous placebo-controlled trials, and existing studies are small, uncontrolled, or inconclusive, raising concerns about their safety and efficacy in humans.
- Contrary to claims that peptides cannot be patented, numerous peptide patents exist, and pharmaceutical companies invest selectively in trials based on potential profitability and competition with existing drugs.
- While the U.S. faces significant health care challenges, including high costs and poor health outcomes, experts caution that bypassing clinical trials for unproven peptide treatments risks public health and undermines incentives for thorough drug evaluation.
